Regulus Therapeutics Inc (NAS:RGLS)

$ 1.49 0 (0%) Market Cap: 97.55 Mil Enterprise Value: 3.44 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 38/100

Regulus Therapeutics Inc To Host Special Update Call Transcript
Sep 20, 2023
Regulus Therapeutics Inc To Host Investor Event (Virtual) Transcript
Sep 06, 2023
Regulus Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q3 2022 Regulus Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$1.63 (-1.52%)

Earnings
Q2 2022 Regulus Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$1.65 (-2.94%)

Earnings
Q1 2022 Regulus Therapeutics Inc Earnings Call Transcript
May 12, 2022

$2.46 (-7.67%)

Earnings
Q4 2021 Regulus Therapeutics Inc Earnings Call Transcript
Mar 10, 2022

$3.02 (+2.69%)

Earnings
Q3 2021 Regulus Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$4.37 (-5.58%)

Earnings
Regulus Therapeutics Inc Announces Strategic Prioritization of RGLS8429 Call Transcript
Oct 12, 2021
Q2 2021 Regulus Therapeutics Inc Earnings Call Transcript
Aug 10, 2021

$7.34 (-2.41%)

Earnings
Regulus Therapeutics Inc at Oppenheimer Rare & Orphan Disease Summit (Virtual) Transcript
May 21, 2021
Q1 2021 Regulus Therapeutics Inc Earnings Call Transcript
May 13, 2021

$8.2 (-4.60%)

Earnings
Regulus Therapeutics Inc Results from the First Cohort of Patients with ADPKD in its Ongoing Phase 1b Clinical Trial of RGLS4326 Call Transcript
May 03, 2021

Regulus Therapeutics Inc Results from the First Cohort of Patients with ADPKD in its Ongoing Phase 1b Clinical Trial of RGLS4326 Call Transcript

May 03, 2021 / 12:30PM GMT

Transcript 10-Q8-K

Operator

Good morning, ladies and gentlemen, and welcome to Regulus Therapeutics Conference Call. My name is Olivia, and I will be your coordinator for today. As a reminder, this conference may be recorded. I would now like to turn the call over to the company. Please proceed.

Crispina Calsada

Regulus Therapeutics Inc. - CFO

Thank you. Good morning, everyone. My name is Crispina Calsada, and I'm the Chief Financial Officer of regular Therapeutics.

Thank you for joining us to discuss the data we announced this morning in a press release regarding the first cohort of our Phase Ib Mechanism Of Action or MOA, study of RGLS4326 in patients with autosomal dominant polycystic kidney disease or ADPKD.

We are joined this morning by Jay Hagan, Chief Executive Officer; Dr. Denis Drygen, Chief Scientific Officer; Dr. Karl Cremer, Head of Clinical Development; and Dr. Ed Lee, Head of the miR-17 program.

During our prepared remarks this morning, Jay will provide a brief summary of the program and today's results, after which we will open the line for

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.